Study on INCB123667 for Treating Platinum-Resistant Ovarian Cancer with High Cyclin E1 Levels

Inclusion Criteria

• Diagnosed with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
• Cancer must be resistant to platinum-based treatments:
  • If only one round of platinum treatment was received, it must have included at least four cycles.
  • If two to four rounds of platinum treatment were received, the cancer must have worsened during or within six months after the last treatment.
• Willing to have a biopsy before starting the study. A recent tissue sample is preferred, but an older sample (up to five years old) is acceptable.
• Have had at least one but no more than four previous treatments since diagnosis, and single-agent therapy is the next suitable option.
• Must have received the drug bevacizumab unless it was not suitable for medical reasons.
• If the tumor is positive for FRα, must have received mirvetuximab soravtansine unless medically exempt.

Exclusion Criteria

• Have a type of ovarian cancer that is endometrioid, clear cell, mucinous, sarcomatous, or low-grade/borderline, or a mixed tumor with these types.
• Have primary platinum-refractory disease, meaning the cancer did not respond to the first platinum treatment or worsened within three months after the last dose.
• If the tumor is positive for FRα but the participant has not received mirvetuximab soravtansine for reasons other than medical exemption.
• Have significant or uncontrolled heart disease within six months before starting the study.
• Have active cancer spread to the brain or spinal cord.
• Have another progressing cancer that needs treatment.